These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21992747)

  • 1. Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study.
    Henderson ST; Poirier J
    BMC Med Genet; 2011 Oct; 12():137. PubMed ID: 21992747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.
    Henderson ST; Vogel JL; Barr LJ; Garvin F; Jones JJ; Costantini LC
    Nutr Metab (Lond); 2009 Aug; 6():31. PubMed ID: 19664276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4
    Xu Q; Zhang Y; Zhang X; Liu L; Zhou B; Mo R; Li Y; Li H; Li F; Tao Y; Liu Y; Xue C
    Clin Nutr; 2020 Jul; 39(7):2092-2105. PubMed ID: 31694759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.
    Pasqualetti P; Bonomini C; Dal Forno G; Paulon L; Sinforiani E; Marra C; Zanetti O; Rossini PM
    Aging Clin Exp Res; 2009 Apr; 21(2):102-10. PubMed ID: 19448381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biobehavioral, and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the ApoE3 Allele Protects Against Neuropsychiatric Symptoms and Psychosocial Deficits.
    Tangwongchai S; Supasitthumrong T; Hemrunroj S; Tunvirachaisakul C; Chuchuen P; Houngngam N; Snabboon T; Tawankanjanachot I; Likitchareon Y; Phanthumchindad K; Maes M
    Mol Neurobiol; 2018 Aug; 55(8):6449-6462. PubMed ID: 29307083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
    Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
    Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease.
    Henderson ST; Morimoto BH; Cummings JL; Farlow MR; Walker J
    J Alzheimers Dis; 2020; 75(2):547-557. PubMed ID: 32310169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E genotype and gender influence response to tacrine therapy.
    Farlow MR; Lahiri DK; Poirier J; Davignon J; Hui S
    Ann N Y Acad Sci; 1996 Dec; 802():101-10. PubMed ID: 8993489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.
    Kálmán J; Juhász A; Rimanóczy A; Palotás A; Palotás M; Szabó Z; Boda K; Márki-Zay J; Janka Z
    Dement Geriatr Cogn Disord; 2003; 16(1):31-4. PubMed ID: 12714797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk.
    Huang YA; Zhou B; Nabet AM; Wernig M; Südhof TC
    J Neurosci; 2019 Sep; 39(37):7408-7427. PubMed ID: 31331998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E genotypes in hospitalized elderly patients with vascular dementia.
    Orsitto G; Seripa D; Panza F; Franceschi M; Cascavilla L; Placentino G; Matera MG; Paris F; Capurso C; Solfrizzi V; Dallapiccola B; Pilotto A
    Dement Geriatr Cogn Disord; 2007; 23(5):327-33. PubMed ID: 17374951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
    De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
    J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults.
    Reger MA; Henderson ST; Hale C; Cholerton B; Baker LD; Watson GS; Hyde K; Chapman D; Craft S
    Neurobiol Aging; 2004 Mar; 25(3):311-4. PubMed ID: 15123336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
    Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
    Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
    Aronson S; Van Baelen B; Kavanagh S; Schwalen S
    Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.